Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery: A systematic review

Thrombosis and Haemostasis

Volumn 107, Issue 1, 2012, Pages 8-14

  Yusuf, Arif M ^a   Warkentin, Theodore E ^b   Arsenault, Kyle A ^a   Whitlock, Richard ^a,b   Eikelboom, John W ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti PF4 H; Antibodies; Cardiac surgery; Heparin

Indexed keywords

ENOXAPARIN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN;

ANTIBODY DETECTION; ANTIBODY TITER; DISEASE ASSOCIATION; DRUG EXPOSURE; EMBASE; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFORMATION RETRIEVAL; LENGTH OF STAY; MEDLINE; MORTALITY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTIBODIES; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HOSPITALIZATION; HUMANS; MALE; MODELS, STATISTICAL; MYOCARDIUM; ODDS RATIO; PLATELET FACTOR 4; PREOPERATIVE PERIOD; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84855298137     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-07-0480     Document Type: Review

References (20)

1. Visentin GP, Ford SE, Scott PJ, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88
2. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of Heparin-Associated Antibodies without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. Circulation 1997; 95: 1242-1246
3. Bennett-Guerrero E, Slaughter TF, White WD, et al. Preoperative anti-PF4/heparin level predicts adverse outcome after cardiac surgery. J Throac Cardiovasc Surg 2005; 130: 1567-1572
4. Selleng S, Malowsky B, Itterman T, et al. Incidence and clinical relevance of antiplatelet factor 4/heparin antibodies before cardiac surgery. Am Heart J 2010; 160: 362-369
5. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335
6. Baroletti S, Piovella C, Fanikos J, et al. Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. Thromb Haemost 2008; 100: 1130-1135
7. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. Thromb Haemost 2005; 94: 132-135
8. Visentin GP, Malik M, Cyganiak KA, et al. Patients treated with Unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996; 128: 376-383
9. Kress DC, Solomon A, McDonald ML, et al. Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgery Outcomes. Ann Thorac Surg 2007; 83: 1737-1743
10. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292
11. Stribling K, Slaughter TF, Houle TT, et al. Beyond the platelet count: Heparin antibodies as independent risk predictors. Am Heart J 2007; 153: 900-906
12. Paparella D, Scrascia G, Galeone A, et al. Formation of anti-platelet factor 4/heparin antibodies following cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J Thorac Cardiovasc Surg 2008; 136: 1456-1463
13. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797-1803
14. Warkentin TE, Sheppard JI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341-346
15. Pathophysiology and Diagnosis of Heparin-Induced Thrombocytopenia. American College of Chest Physicians 2010. Available at: http://www.chestnet.org/accp/ article/chest-physician/pathophysiology-and-diagnosis-heparin-inducedthrombocytopenia. Accessed August 23, 2011.
16. Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
17. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Warkentin TE, Greinacher A. Chest 2004; 126: 3115-3375
18. Ruf KM, Bensadoun ES, Davis GA, et al. A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011; 105: 553-559
19. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678-684
20. Aquino RS, Pereira MS, Vairo BC, et al. Heparins from porcine and bovine intestinal mucosa: Are they similar drugs? Thromb Haemost 2010; 103: 1005-1015